These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The face of HIV and AIDS: can we erase the stigma? Kavouni A; Catalan J; Brown S; Mandalia S; Barton SE AIDS Care; 2008 Apr; 20(4):485-7. PubMed ID: 18449827 [TBL] [Abstract][Full Text] [Related]
28. Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Bassichis B; Blick G; Conant M; Condoluci D; Echavez M; Eviatar J; Gold MH; Hamilton T; Hanke CW; Humble G; LaMarca A; Daro-Kaftan E; Mest D; Pierone G Dermatol Surg; 2012 Jul; 38(7 Pt 2):1193-205. PubMed ID: 22759256 [TBL] [Abstract][Full Text] [Related]
29. Poly-l-lactic acid for correction of localized facial lipoatrophy in an otherwise healthy young woman. Burgess CM Dermatol Surg; 2009 May; 35(5):881-4. PubMed ID: 19389088 [No Abstract] [Full Text] [Related]
30. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597 [TBL] [Abstract][Full Text] [Related]
31. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]. Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM; HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777 [TBL] [Abstract][Full Text] [Related]
32. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. Carey D; Baker D; Petoumenos K; Chuah J; Rogers GD; Watson J; Cooper DA; Emery S; Carr A; HIV Med; 2009 Mar; 10(3):163-72. PubMed ID: 19245538 [TBL] [Abstract][Full Text] [Related]
33. Cosmetic use of poly-l-lactic acid: a retrospective study of 130 patients. Palm MD; Woodhall KE; Butterwick KJ; Goldman MP Dermatol Surg; 2010 Feb; 36(2):161-70. PubMed ID: 20039924 [TBL] [Abstract][Full Text] [Related]
34. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. Carey DL; Baker D; Rogers GD; Petoumenos K; Chuah J; Easey N; Machon K; Cooper DA; Emery S; Carr A; J Acquir Immune Defic Syndr; 2007 Dec; 46(5):581-9. PubMed ID: 18193500 [TBL] [Abstract][Full Text] [Related]
35. Soft tissue augmentation using sculptra. Humble G; Mest D Facial Plast Surg; 2004 May; 20(2):157-63. PubMed ID: 15643584 [TBL] [Abstract][Full Text] [Related]
36. Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for restoration of soft tissue volume. Schierle CF; Casas LA Aesthet Surg J; 2011 Jan; 31(1):95-109. PubMed ID: 21239677 [TBL] [Abstract][Full Text] [Related]
37. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA). Jagdeo J; Ho D; Lo A; Carruthers A J Am Acad Dermatol; 2015 Dec; 73(6):1040-54.e14. PubMed ID: 26481056 [TBL] [Abstract][Full Text] [Related]
38. Investigator global evaluations of efficacy of injectable poly-L-lactic acid versus human collagen in the correction of nasolabial fold wrinkles. Brandt FS; Cazzaniga A; Baumann L; Fagien S; Glazer S; Kenkel JM; Lowe NJ; Monheit GD; Narins RS; Rendon MI; Rohrich RJ; Werschler WP Aesthet Surg J; 2011 Jul; 31(5):521-8. PubMed ID: 21719865 [TBL] [Abstract][Full Text] [Related]
39. Soft-tissue augmentation and the role of poly-L-lactic acid. Vleggaar D Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):46S-54S. PubMed ID: 16936544 [TBL] [Abstract][Full Text] [Related]
40. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy]. Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]